Author

V. Cerullo

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Immunology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:mouse· 3 Research Focus:cancer & tumor microenvironment· 2 Approach:deep learning· 2 Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Assay:proteomics· 2 Organism:human· 1 Approach:statistical model· 1

Frequent Co-Authors

B. Martins· 3 shared E. Ylosmaki· 3 shared F. Hamdan· 3 shared M. Fusciello· 3 shared S. Feola· 3 shared T. Viitala· 3 shared J. Chiaro· 2 shared A. Di Lieto· 1 shared

Activity by Year

2021-2021 · peak 4/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

B. Martins

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

A novel immunopeptidomic-based pipeline for the generation of personalized oncolytic cancer vaccines

S. Feola, J. Chiaro, B. Martins, S. Russo, M. Fusciello, E. Ylosmaki, F. Hamdan, M. Feodoroff, G. Antignani, T. Viitala, S. Pesonen, M. Gronholm, R. M. M. Branca, J. Lehtio, V. Cerullo

The paper describes a pipeline for generating personalized oncolytic cancer vaccines using immunopeptidomic data and validates it in a murine colon tumor model.

bioRxiv · Jun 8, 2021Cancer Biology

A personalized anti-cancer vaccine for melanoma based on an approved vaccine against measles, mumps, and rubella

E. Ylosmaki, M. Fusciello, A. Uoti, S. Feola, B. Martins, K. Aalto, F. Hamdan, J. Ciaro, T. Viitala, V. Cerullo

This paper repurposes an approved MMR vaccine in a PeptiENV platform to enhance anti-melanoma immunity and improve response to checkpoint inhibitors.

bioRxiv · Jun 7, 2021 · PreprintImmunology

Computationally prioritized drugs inhibit SARS-CoV-2 infection and syncytia formation

A. Serra, M. Fratello, A. Federico, R. Ojha, R. Provenzani, E. Tasnadi, L. Cattelani, G. del Giudice, P. A. S. Kinaret, L. A. Saarimaki, A. Pavel, V. Cerullo, O. Vapalahti, P. Horvath, A. Di Lieto, , D. Greco

The paper identifies two compounds that inhibit SARS-CoV-2 infection and syncytia formation through computational prioritization and in vitro testing.

bioRxiv · Apr 15, 2021Pharmacology & Toxicology

Novel personalized cancer vaccine platform based on Bacillus Calmette-Guerin

E. Ylosmaki, B. Martins, M. Fusciello, S. Feola, F. Hamdan, J. Chiaro, L. Ylosmaki, M. J. Vaughan, T. Viitala, P. S. Kulkarni, V. Cerullo

This paper develops a BCG-based cancer vaccine platform that enhances anti-tumor immune responses by attaching tumor-specific peptides to BCG, improving therapeutic outcomes in mouse models.

bioRxiv · Mar 5, 2021Cancer Biology